Discussing the Option of Canakinumab in NSCLC


Edward B. Garon, MD, MS, discusses the mechanism of action of canakinumab.

Edward B. Garon, MD, MS, professor of medicine, Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses the mechanism of action of canakinumab (Ilaris).

Canakinumab is an interleukin-1beta inhibitor (IL-1β) being evaluated as a potential treatment option for patients with non–small cell lung cancer (NSCLC).

Within the phase 3 CANOPY-A study (NCT03447769), adjuvant canakinumab is being explored in patients with completely resected NSCLC. However, the agent failed to meet its primary end point of disease-free survival, according to data presented at the 2022 ESMO.


0:08 | Canakinumab is a high-affinity monoclonal antibody directed against an interleukin-1beta. IL-1β has been considered a key mediator of inflammation. One of the unique aspects of canakinumab is that it is an approved drug in many countries, including the United States, for a variety of inflammatory disorders.

0:28 | There has been a tremendous amount of preclinical data looking at IL-1β and other mediators of inflammation in lung cancer. Prior to the development of canakinumab, there was much less clinical data available looking at this pathway.

Related Videos
Related Content